💊 Obat A-Z 🧬 Target 🛠 Alat 📚 Panduan
Semua Obat Kelas Obat Area Terapeutik Efek Samping
Panduan Glosarium Linimasa
Perbandingan Perjalanan Obat Famili Obat
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Rivastigmine

CHEMBL636 Phase 4 Disetujui Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
250.3 g/mol
LogP
2.3
Phase
4

A cholinesterase inhibitor used to treat mild to moderate dementia associated with Alzheimer's disease and Parkinson's disease, by preventing the breakdown of acetylcholine in the brain. It is available as capsules, oral solution, and a skin patch that many patients find easier to tolerate.

Berat Molekul

250,3400 g/mol

LogP

2,30

TPSA

32,80 Ų

Lipinski RO5

Lulus

Area Terapeutik

Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Generalized Anxiety Disorder Multiple Sclerosis Stroke Major Depressive Disorder

Mekanisme Kerja

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Struktur 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1

                

                

                
                

                    
InChI

                    
InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C14H22N2O2

                    

                    
                    

                        
HBD / HBA

                        
- / 3

                    

                    
                    

                        
Ikatan yang Dapat Dirotasi

                        
5

                    

                    
                    
                    

                        
Atom Berat

                        
18

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Pertanyaan yang Sering Diajukan

                

                    
                    

                        
                        

                            
A cholinesterase inhibitor used to treat mild to moderate dementia associated with Alzheimer's disease and Parkinson's disease, by preventing the breakdown of acetylcholine in the brain. It is available as capsules, oral solution, and a skin patch that many patients find easier to tolerate.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Rivastigmine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL636.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 77991.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Penyangkalan Medis

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.